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Palonosetron is a potent 5-HT3 receptor antagonist with a unique structure and some unusual properties.
Here we explore the properties of palonosetron at heterologously expressed 5-HT3A and 5-HT3AB re-
ceptors. We used receptors expressed in HEK293 cells, and functionally analysed them using a membrane
potential sensitive dye in a Flexstation, which revealed IC50s of 0.24 nM and 0.18 nM for 5-HT3A and 5-
HT3AB receptors respectively. Radioligand binding studies with [
3H]palonosetron revealed similar Kds:
0.34 nM for 5-HT3A and 0.15 nM for 5-HT3AB receptors. Kinetic studies showed palonosetron association
and dissociation rates were slightly faster in 5-HT3AB than 5-HT3A receptors, and for both subtypes
dissociation rates were ligand-dependent, with antagonists causing more rapid dissociation than ago-
nists. Similar ligand effects were not observed for [3H]granisetron dissociation studies. These data
support previous studies which show palonosetron has actions distinct to other 5-HT3 receptor antag-
onists, and the slow rates observed for agonist induced dissociation (t1/2 > 10 h) could at least partly
explain the long duration of palonosetron effects in vivo.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license. 1. Introduction
5-HT3 receptors are members of the Cys-loop family of ligand-
gated ion channels, membrane proteins that are responsible for
fast excitatory and inhibitory synaptic neurotransmission in central
and peripheral nervous systems, and the targets for a number of
important therapeutics. 5-HT3 receptor antagonists are routinely
used in the management of post-operative, radiotherapy-induced
and chemotherapy-induced nausea and vomiting and for treating
irritable bowel syndrome in patients that do not respond
adequately to conventional therapies. A range of other therapeutic
applications has also been suggested (reviewed in (Thompson and
Lummis, 2007;Walstab et al., 2010)). Antagonists are often referred
to as the “setrons”, and include ondansetron, granisetron and pal-
onosetron (Fig. 1). These drugs are potent (Kd ¼ nM  pM), long
lived in vivo, and most are highly selective for the 5-HT3 receptor.nin); HEK, human embryonic
half-maximal inhibition; Kd,
: þ44 1223 333345.
r Ltd. Open access under CC BY license.Furthermore, they are usually well tolerated and display only mild,
transient side-effects, making them the preferred choice of drug in
most instances (Aapro, 2004; Blower, 1995; Eglen et al., 1995;
Hirata et al., 2007).
Palonosetron has a different structure from the other 5-HT3
antagonists (Fig. 1), and some distinctive properties. The ﬁrst
published accounts of these properties were in 1995, when radio-
ligand binding experiments demonstrated that it bound to 5-HT3
receptors with high potency and selectivity, and in vivo data
showed an anti-emetic efﬁcacy greater than or equal to that of
ondansetron or granisetron (Bonhaus et al., 1995; Eglen et al., 1995;
Wong et al., 1995). At that time, however, it was not clear that there
are multiple 5-HT3 receptor subunits, (A-E), in addition to alter-
native splice variants, thus providing the potential for a wide range
of different 5-HT3 receptor subtypes. Heteromeric assemblies of 5-
HT3A plus 5-HT3C, 5-HT3D or 5-HT3E subunits have not yet been
extensively studied, but their biophysical properties appear similar
to homomeric 5-HT3A receptors (see (Niesler, 2011) and (Walstab
et al., 2010) for reviews). 5-HT3AB receptors, however, have been
extensively investigated in heterologous systems, and have
differing concentrationeresponse curves (increased EC50 values
and shallower Hill slopes), increased single channel conductance
(5-HT3A ¼ sub-pS; 5-HT3AB ¼ 16e30 pS), an increased rate of
desensitisation, reduced Ca2þ permeability and a non-linear cur-
rentevoltage relationship (Davies et al., 1999; Kelley et al., 2003; 
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Fig. 1. Chemical structures of 5-HT and clinically used 5-HT3 receptor competitive
antagonists.
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afﬁnity and association and dissociation rates of palonosetron in 5-
HT3A and 5-HT3AB receptors, we here explore the effects of pal-
onosetron on 5-HT3 receptor function and binding in these receptor
subtypes.2. Materials and methods
2.1. Materials
All cell culture reagents were obtained from Gibco BRL (Paisley, U.K.), except
foetal calf serum which was from Labtech International (Ringmer, U.K.). [3H]grani-
setron (84 Ci mmol1) was from PerkinElmer (Boston, Massachusetts, USA). [3H]-
palonosetron (37.2 Ci/mmol) was custom synthesised for Helsinn Healthcare
(Lugano, Switzerland), and both this and the unlabelled form of palonosetron were
kindly gifted by Helsinn Healthcare (Lugano, Switzerland). All other reagents were of
the highest obtainable grade.2.2. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained on 90 mm tissue
culture plates at 37 C and 7% CO2 in a humidiﬁed atmosphere. Theywere cultured in
DMEM:F12 (Dulbecco’s Modiﬁed Eagle Medium/Nutrient Mix F12 (1:1)) with Glu-
taMAX I media containing 10% foetal calf serum and passaged when conﬂuent. For
radioligand binding studies cells in 90 mm dishes were transfected using PEI and
incubated for 3e4 days before use. For functional studies cells were plated on 96
well plates, transfected using the Neon transfection system (Invitrogen) and incu-
bated 1e2 days before assay. Mutagenesis reactions were performed using Quik-
Change (Agilent Technologies Inc., CA, USA) using human 5-HT3A or 5-HT3B receptor
subunit cDNA (accession numbers: P46098 or O95264) in pcDNA3.1 (Invitrogen,
Paisley, UK). Subunit numberings have been altered to the aligning residues in the
mouse 5-HT3A receptor.Fig. 2. Typical Flexstation responses of HEK293 cells expressing 5-HT3A and 5-HT3AB recepto
responses, which are different in homomeric and heteromeric receptors. F ¼ arbitrary ﬂuo2.3. Radioligand binding
Methods were as previously described (Lummis et al., 1993), with minor
modiﬁcations. Brieﬂy, transfected HEK293 cells were washed twice with phos-
phate buffered saline (PBS) at room temperature and scraped into 1 ml of ice-cold
HEPES buffer (10 mM, pH 7.4) containing the following proteinase inhibitors (PI):
1 mM EDTA, 50 mg ml1 soybean trypsin inhibitor, 50 mg/ml bacitracin and
0.1 mM phenylmethylsulphonyl ﬂuoride. Cells were homogenised, freeze-thawed,
washed with HEPES buffer, and 50 mg of the crude cell membrane preparation
incubated in 0.5 ml HEPES buffer containing [3H]granisetron or [3H]palonosetron
at a range of concentrations for saturation binding, or at 0.3 nM and 0.1 nM
respectively for competition binding and association/dissociation studies. Non-
speciﬁc binding was determined using 10 mM quipazine. Equilibrium reactions
were incubated for at least 1 h or 24 h for [3H]granisetron or [3H]palonosetron
respectively at 4 C. Dissociation was initiated with unlabelled ligands to give a
ﬁnal concentrations of 100 mM (5-HT), 10 mM (quipazine), 1 mM (MDL72222) or
100 nM (palonosetron). All samples were terminated by vacuum ﬁltration using a
Brandel cell harvester onto GF/B ﬁlters pre-soaked in 0.3% polyethyleneimine.
Radioactivity was determined by scintillation counting using a Beckman
LS6000SC (Fullerton, California, USA).
2.4. Fluorescent studies
These were performed as previously described (Price and Lummis, 2005).
Brieﬂy, cells were gently rinsed twice with buffer (10 mM HEPES, 115 mM NaCl,
1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, pH 7.4) and 100 ml ﬂuorescent
membrane-potential sensitive dye (Molecular Devices) added. Cells were then
incubated at room temperature for 45 min before assay. For inhibition studies,
palonesetron was added either with the dye, ensuring a 45 min pre-incubation, or
simultaneously with 5-HT (co-application). Fluorescence was measured in a
FLEXstation (Molecular Devices Ltd., Wokingham, UK) every 2 s for 200 s using the
acquisition software SOFTmax PRO v4.3. Control (buffer alone) or 5-HT (0.001 mMe
30 mM) was added to each well at 20 s. Typical responses are shown in Fig. 2.
2.5. Data analysis
Data were analysed by iterative curve ﬁtting using Prism software (GraphPad,
San Diego, California, USA). Determination of Ki values was performed using the
ChengePrusoff equation. Values are presented as mean  SEM, n ¼ 3e6.
3. Results
3.1. Functional studies
Examination of palonosetron inhibition of 5-HT3 receptors
expressed in oocytes revealed very slow recovery after washout,
with <10% of the original response being recovered after a 10 min
wash (data not shown). We therefore determined the inhibitory
effects of palonosetron on 5-HT-induced responses using 5-HT3
receptors expressed in HEK293 cells loaded with membrane sen-
sitive ﬂuorescent dye where washout is not required. Preliminary
experiments revealed palonosetron required at least 5 min incu-
bation before application of 5-HT to reveal its full inhibition, and
thereafter it was preincubated for 45 min. Data revealed different
apparent potencies of palonosetron at 5-HT3A receptors, depending
upon whether it was preincubated (pIC50 ¼ 9.73  0 0.13;rs. 5-HT at various concentrations (0e30 mM) was added at 20 s. Note the shapes of the
rescent units.
Fig. 3. Inhibition of 5-HT-induced responses in HEK293 cells. A: Palonosetron is more potent when pre-applied ( ) than when co-applied ( ) with 5-HT; example in cells expressing
5-HT3A receptors. B. Palonosetron has similar IC50s at 5-HT3A and 5-HT3AB receptors. Parameters derived from these data are given in Section 3.1.
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IC50 ¼ 83 nM, n ¼ 4), suggesting that palonosetron has a relatively
slow on rate, and in particular that its on rate is slower than that of
5-HT (Fig. 3A).
With a 45 min preincubation, palonosetron inhibition of 5-HT-
induced responses (Fig. 3B) revealed sub-nanomolar IC50s at
both 5-HT3A and 5-HT3AB receptors: pIC50 ¼ 9.61  0.13;
(IC50 ¼ 0.24 nM), and 9.73  0.27; (IC50 ¼ 0.18 nM) respectively
(n ¼ 4).
Examination of 5-HT concentration response curves in the
presence of 0, 0.1 nM or 0.3 nM palonosetron revealed increased
EC50s and decreased maximal responses with increasing pal-
onosetron concentrations (Fig. 4).
3.2. Radioliogand binding
Palonosetron displacement of the 5-HT3-speciﬁc ligand [3H]
granisetron revealed similar potencies at 5-HT3A and 5-HT3AB re-
ceptors. pIC50s ¼ 9.22  0.05; (IC50 ¼ 0.60 nM; Ki ¼ 0.3 nM), and
9.14 0 0.18 (IC50¼ 0.71 nM; Ki¼ 0.35 nM) respectively. SaturationFig. 4. Functional and radioligand binding data suggest similar effects of palonosetron at 5-
receptor-expressing cells; EC50 values increase and Fmax values decrease as [palonosetron] i
Fmax values of 100%, 70% and 40% for 0, 0.1 nM and 0.3 nM palonosetron in 5-HT3A recepto
panel: typical radioligand binding curves for 5-HT3A and 5-HT3AB receptors.experiments with a range of [3H]palonosetron concentrations
revealed high afﬁnity binding with Kd values of 0.34  0.04 and
0.15  0.04 nM at 5-HT3A and 5-HT3AB receptors respectively.
Typical data is shown in Fig. 4.
3.3. Association and dissociation rates
Association of [3H]palonosetron was complete in w30 min at
both 5-HT3A and 5-HT3AB receptors, with t1/2 values of 4.1
(k ¼ 0.16  0.03) and 2.0 min (k ¼ 0.35  0.06) respectively
(signiﬁcantly different, t-test, p < 0.05). This is slower than previ-
ously reported where association was complete in under 10 min
(Wong et al., 1995).
Our dissociation rates were also slower than previously re-
ported, and were also strongly dependent on the ligand used for
dissociation. An excess of unlabelled palonosetron gave t1/2 values
for dissociation of 1.5 h and 1.0 h for 5-HT3A and 5-HT3AB receptors
respectively, with values of 2.3 h and 1.7 h when an excess of
MDL72222 was used. However when the agonists 5-HT or quipa-
zine were used, t1/2 values were >10 h. Data are shown in Table 1HT3A and 5-HT3AB receptors. Top: Typical Flexstation data from 5-HT3A and 5-HT3AB
ncreases. In this typical example EC50s are 0.16 mM, 0.35 mM and 0.97 mM with relative
rs, and 0.12 mM (100%), 0.27 mM (62%) and 1.6 mM (28%) in 5-HT3AB receptors. Lower
Table 1
[3H] palonosetron and [3H] granisetron binding dissociation rates with different
displacing ligands using 5-HT3 receptors expressed in HEK293 cells.* ¼ signiﬁcantly
different to 5-HT3A receptors, t-test, p < 0.05.
5-HT3A receptors 5-HT3AB receptors
k1 (mean  S.E.M) t1/2 (h) k1 (mean  S.E.M) t1/2 (h)
[3H] palonosetron
5-HT 0.032  0.005 21.9 0.057  0.008* 12.1
Quipazine 0.056  0.003 12.5 0.068  0.003* 10.1
MDL72222 0.29  0.03 2.3 0.41  0.04* 1.7
Palonosetron 0.44  0.05 1.5 0.68  0.08* 1.0
[3H] granisetron
5-HT 0.14  0.020 4.6 0.17  0.023 4.0
MDL72222 0.15  0.023 4.8 0.16  0.021 4.2
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agonists speciﬁc binding does not approach background levels until
2e5 days after dissociation is initiated. Similar experiments using
[3H]granisetron revealed no differences in rates using agonists or
antagonists (Table 1 and Fig. 6).4. Discussion
Palonosetron is a potent 5-HT3 receptor antagonist which is
proving to be superior to other 5-HT3 receptor antagonists for the
treatment of acute and delayed post-operative, radiotherapy-
induced and chemotherapy-induced nausea and vomiting. The
unusual properties of palonosetron, which have been proposed to
explain its superiority, include allosteric interactions, positive co-
operativity and palonosetron-triggered 5-HT3 receptor internali-
zation (Rojas et al., 2008, 2010). Internalizationwas not explored in
our association and dissociation rate experiments, as this process
would not occur at the temperatures at which these experiments
were performed, but the slow palonosetron dissociation rate
shown here could provide an additional or alternative explanation
to internalization: our data show palonosetron has the ability toFig. 5. Association and dissociation curves for [3H]palonosetron using HEK293 cells expressi
receptors, with maximal levels being reached within 30 min. Dissociation rates were slo
(quipazine). Parameters derived from these data are given in Section 3.3.inhibit 5-HT3 receptors for considerably longer than the more
established 5-HT3 receptor antagonists such as ondansetron and
granisetron, which could result in a prolonged anti-emetic
behaviour.
Palonosetron is a potent inhibitor of 5-HT-induced increases in
ﬂuorescence of a membrane potential sensitive dye. Inhibition of
5-HT3 receptor function at low concentrations was expected as
palonosetron has an afﬁnity for 5-HT3 receptors that is greater
than other commonly used 5-HT3 receptor antagonists (e.g.
NG108-15 cells Kd ¼ 0.05 nM (Wong et al., 1995), human hippo-
campus Kd ¼ 0.15 nM (Wong et al., 1995), transfected HEK293
cells Kd ¼ 0.2 nM (Rojas et al., 2008)). The slow dissociation rates
we observed (t1/2 ¼ 1e22 h) differ from previous studies (t½ ¼ 8e
10 min) (Wong et al., 1995), but are consistent with the slow re-
covery from palonosetron-induced 5-HT3 receptor inhibition we
observed in our preliminary experiments in oocytes, which pre-
cluded us from using them in this study. Somewhat similar data
were observed by Rojas et al. (2008), who showed that 53  11%
of [3H]palonosetron remained associated with 5-HT3 receptor-
expressing HEK293 cells after a 2.5 h wash. This is akin to our
data: e.g. dissociation of [3H]palonosetron from 5-HT3A receptors
in the presence of MDL72222 resulted in 67  7% (n ¼ 4) of [3H]
palonosetron remaining after 2 h. Subsequent experiments by
Rojas et al. (2010) suggested a difference between cells and cell-
free membranes, with 65% [3H]palonosetron remaining in cells
after a 60 min wash, but only 2% remaining in a cell-free mem-
brane preparation (Rojas et al., 2010). Our preparation is similar to
their cell free preparation, (i.e. it does not contain whole cells)
although it is not washed as extensively, and our cells were not
treated with trypsin; thus it may be that the different procedures
can signiﬁcantly effect binding characteristics.
We did not observe any major difference between the effects of
palonosetron at homomeric (5-HT3A) and heteromeric (5-HT3AB)
receptors. 5-HT3A receptors may predominate in the CNS, while 5-
HT3AB receptors may be more abundant in the PNS. Nevertheless,
both 5-HT3A and 5-HT3B subunits, and indeed the other three
subunits in this family (5-HT3Ce5-HT3E), are widely distributed inng 5-HT3A and 5-HT3AB receptors. Association was rapid for both 5-HT3A and 5-HT3AB
wer, although were faster with antagonists (MDL72222, palonosetron) than agonists
Fig. 6. [3H]granisetron and [3H]palonosetron dissociation curves in 5-HT3A receptors. Dissociation curves for [3H]granisetron using HEK293 cells expressing 5-HT3A receptors using
5-HT (agonist) or MDL72222 (antagonist) are superimposable. However data from [3H]palonosetron dissociation experiments reveal a clear distinction between agonist and
antagonist displacement rates. Data from these curves are shown in Table 1.
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indicate similar palonosetron Kds at 5-HT3A and 5-HT3AB receptors,
consistent with previous work showing that competitive antago-
nists (with one exception, see below) do not show major differ-
ences in potency between these two receptor subtypes. This is
because the binding site for these compounds is located between
two 5-HT3A subunits, which assemble as part of the 5-HT3AB
pentamer (Lochner and Lummis, 2010; Thompson et al., 2011). The
only competitive antagonist that has been identiﬁed with distinct
afﬁnities at 5-HT3A and 5-HT3AB receptors is VUF10166, and the
different in afﬁnities is due to an allosteric binding site at an A þ B-
interface (Thompson et al., 2012). An allosteric mechanism has also
been previously suggested for palonosetron (Moura Barbosa et al.,
2010) using computational data, and allosteric binding character-
istics have been reported (concave Scatchard plots and Hill slopes
of 1.5 (Rojas et al., 2008). Our data showing increased EC50s and
decreased maximal responses with increasing concentrations of
palonosetron are consistent with a non-competitive mode of action
of this compound, i.e. action at an allosteric site. However they are
also consistent with an irreversible competitive antagonist, and,
given the slow off rates of [3H]palonosetron, we consider this is the
correct interpretation, and that these data reﬂect the fact that
palonosetron does not signiﬁcantly dissociate from the receptor
during these experiments.
We did observe a difference in [3H]palonosetron dissociation
rates depending on the unlabelled ligand used for displacement,
with antagonists resulting in more rapid dissociation compared to
agonists; similar ﬁndings have been previously observed for native
5-HT3 receptors in NG108-15 cells, and 5-HT3A receptors in HEK293
cells (Bonhaus et al., 1995). These authors suggest that binding of
agonists to unoccupied binding sites can increase the receptors
afﬁnity for prebound ligands and thereby slow their dissociation.
We propose there is a similar mechanism in our experiments. At
the start of the dissociation experiments up to ﬁve potential
binding sites could be occupied by [3H]palonosetron in 5-HT3A
receptors, with less (1e3) in 5-HT3AB receptors. Subsequent oc-
cupancy of a binding site by unlabelled palonosetron or another
competitive antagonist such as MDL72222 would not alter the state
of the receptor, while agonist binding likely causes entry into a high
afﬁnity desensitized state. Palonosetron, in one or more of the
remaining binding sites, would then only dissociate slowly.
Our data also show that both association and dissociation rates
are slightly faster for 5-HT3AB receptors, which may be due to
subtle difference in structure of this receptor; it is known, for
example, that these receptors are more prone to spontaneous
opening (Hu and Peoples, 2008). Our data reveal that agonists have
a similar effect in homomeric and heteromeric receptors, providing
evidence that there is more than one orthosteric (A þ A-) binding
site in heteromeric receptors.In conclusion we have shown that palonosetron binds with
similar afﬁnities at 5-HT3A and5-HT3AB receptors.Weobserved that
in both receptor subtypes there is slow dissociation of [3H]pal-
onosetron, and its rate is ligand-dependent. This slow dissociation,
which is particularly pronounced in the presence of agonists, pro-
vides a possible additional or alternative explanation for the long
lasting therapeutic effects of palonosetron. Our conclusions are
strongly supported by a study published during revision of this
manuscript (Hothersall et al., 2013). These authors used [3H]grani-
setron binding and ELISA to monitor COS-7 cells transfected with 5-
HT3 receptors. Their data, obtained predominantly from live cells
incubated at a variety of temperatures, indicate that palonosetron
acts as a pseudo-irreversible antagonist causing prolonged inhibi-
tion due to slowdissociation,withno contribution fromendocytosis.
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